Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide‐enhanced magnetic resonance imaging
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: To examine the efficacy of FTY720 as a new agent to reduce inflammatory activity in an animal model of multiple sclerosis (MS) by in vivo macrophage tracking. Material and Methods: FTY720 was used for treatment of rats in a model of chronic relapsing experimental autoimmune encephalomyelitis (EAE) at an oral dose of 0.3 mg/kg/day. Magnetic resonance imaging (MRI) based on in vivo tracking of macrophages labeled with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, immunohistological staining (IHC), and neurological readouts was used to study the burden of disease in treated and untreated animals. Results: While untreated animals showed severe paralysis of the hind paws, intense accumulation of macrophages in brain tissue, and areas of blood‐brain barrier (BBB) disruption, FTY720‐treated animals displayed no signs of inflammatory activity or neurological impairment. These observations were made for both acute phase and first relapse. Conclusion: Tracking of macrophages by MRI provides direct evidence of the immunomodulatory efficacy of FTY720 in the EAE model and correlates well with neurological symptoms and histology. J. Magn. Reson. Imaging 2004;20:16–24. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kooi, M. E., Cappendijk, V. C., Cleutjens, K. B. J. M., Kessels, A. G. H., Kitslaar, P. J. E. H. M., Borgers, M., Frederik, P. M., Daemen, M. J. A. P., & van Engelshoven, J. M. A. (2003) · Circulation · doi:10.1161/01.cir.0000068315.98705.cc · Cited by 798 · cited 1×
“USPIO-based cell labeling has already been introduced in human studies, primarily for MR lymphography (18,19) and recently as a noninvasive tool to discriminate between low- and high-risk atherosclerotic plaques (20).”
MethodKatz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387
HAWKINS, C. P., MUNRO, P. M. G., MACKENZIE, F., KESSELRING, J., TOFTS, P. S., BOULAY, E. P. G. H. D., LANDON, D. N., & McDONALD, W. I. (1990) · Brain · doi:10.1093/brain/113.2.365 · Cited by 219
Cited by
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Recent advances in iron oxide nanocrystal technology for medical imaging☆
COROT, C., ROBERT, P., IDEE, J., & PORT, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.013 · Cited by 1,465
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers
Wahajuddin, & Arora (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30320 · Cited by 1,117
Brinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500
Nanoparticles for Brain Drug Delivery
Masserini, M. (2013) · ISRN Biochemistry · doi:10.1155/2013/238428 · Cited by 489
Mikita, J., Dubourdieu-Cassagno, N., Deloire, M. S., Vekris, A., Biran, M., Raffard, G., Brochet, B., Canron, M.-H., Franconi, J.-M., Boiziau, C., et al. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458510379243 · Cited by 358
Modo, M., Hoehn, M., & Bulte, J. W. M. (2005) · Molecular Imaging · doi:10.1162/15353500200505145 · Cited by 294
Vellinga, M. M., Oude Engberink, R. D., Seewann, A., Pouwels, P. J. W., Wattjes, M. P., van der Pol, S. M. A., Pering, C., Polman, C. H., de Vries, H. E., Geurts, J. J. G., et al. (2008) · Brain · doi:10.1093/brain/awn009 · Cited by 183
“Most animal and human studies exploring USPIO in inflammatory CNS diseases have used ferumoxtran-10, (Dousset et al., 1999b; Floris et al., 2004; Rausch et al., 2004; Brochet et al., 2006), although other compounds were previously studied (Xu et al.”
BackgroundTomitaka, A., Vashist, A., Kolishetti, N., & Nair, M. (2023) · Nanoscale Advances · doi:10.1039/d3na00180f · Cited by 45
Metadata
- Authors
- Rausch, M., Hiestand, P., Foster, C. A., Baumann, D. R., Cannet, C., & Rudin, M.
- Venue
- Journal of Magnetic Resonance Imaging
- Publisher
- Wiley
- Published
- 2004-06-21
- Volume
- 20
- Issue
- 1
- Pages
- 16-24
- ISSN
- 1053-1807 (ISSN-L)
- 1522-2586
- OpenAlex
- W2067822704
- Cited by
- 109
- References
- 3
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.